Although the standard of care treatment for multiple sclerosis involves immunomodulatory therapy administered via injection, the availability of an oral disease modifying therapy is the latest advance in the treatment of this devastating illness. This paper looks at what the data tells us about the future of new oral drugs in the MS pipeline.
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: